Skip to main content

Permanent Trial Closure: ALC3

permanent closure of the ALC3 trial
Notification of the permanent closure of the ALC3 trial; A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML).
 
This randomized phase III trial studies cytarabine and daunorubicin hydrochloride or idarubicin and cytarabine with or without vorinostat to see how well they work in treating younger patients with previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as cytarabine, daunorubicin hydrochloride, idarubicin, and vorinostat, work in different ways to stop the growth of cancer cells, either by killing the cells, stopping them from dividing, or by stopping from spreading.
 
The permanent closure letter can be found under the Toolbox - Reports - Trial Closure.
 
Primary Publication

Garcia-Manero, Guillermo;Podoltsev, Nikolai A.;Othus, Megan;Pagel, John M.;Radich, Jerald P.;Fang, Min;Rizzieri, David A.;Marcucci, Guido;Strickland, Stephen A.;Litzow, Mark R.;Savoie, M. Lynn;Medeiros, Bruno C.;Sekeres, Mikkael A.;Lin, Tara L.;Uy, Geoffrey L.;Powell, Bayard L.;Kolitz, Jonathan E.;Larson, Richard A.;Stone, Richard M.;Claxton, David;Essell, James;Luger, Selina M.;Mohan, Sanjay R.;Moseley, Anna;Appelbaum, Frederick R.;Erba, Harry P. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AMLLeukemia Leukemia:38(1):58 -66,2024

Registry Results: NCT01802333: Study results are available on www.clinicaltrials.gov